Arthritis Drug Of Japan’s Chugai, Roche Shows Well In Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
A drug developed by Japan's Chugai Pharmaceutical and Switzerland's Roche Holdings is showing favorable results midway through a Phase III study for reducing joint damage from rheumatoid arthritis. The drug is Actemra (tocilizumab), the subject of a delay by the U.S. FDA in reviewing it for possible approval. FDA wanted more data related to manufacturing and labeling, according to Roche. Researchers said the ongoing study shows Actemra to be effective in slowing the progression of bone erosion when used over a four-week period with methotrexate. The drug is expected to be a billion-dollar seller for the two drug makers once approved. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.